On February 17, 2026, EVR Research announced a new investment in Ingevity (NGVT), acquiring 100,000 shares valued at $5.92 million. This move, detailed in an SEC filing, marks a strategic addition to EVR’s portfolio, representing 3.19% of its $185.31 million in U.S. equity assets as of year-end 2025.
This investment is significant as Ingevity has demonstrated robust performance, with its shares climbing 56% over the past year, significantly outpacing the S&P 500’s 19% gain. The company’s focus on specialty chemicals and activated carbon solutions positions it well amidst increasing demand for emissions control and infrastructure spending, making it an attractive choice for investors seeking cyclical exposure in a selective market.
For professionals looking to understand the implications of this transaction, it highlights a strategic pivot towards industrial and materials sectors, reinforcing the importance of cyclical stocks in a balanced portfolio. I recommend diving deeper into the full article for a comprehensive analysis of this development.
Source: fool.com